ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2017 - 2023)
ProQR Therapeutics (PRQR) posted Income from Non-Controlling Interests of $315691.2 for Q3 2023, up 1711.94% sequentially from $17422.8 in Q2 2023, and up 2136.43% YoY from $14115.8 in Q3 2022.
Powered by 
Analysis
ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2017 - 2023) Analysis & Trends
ProQR Therapeutics has reported Income from Non-Controlling Interests for 8 years, with the latest figure at $315691.2 in Q3 2023.
- Quarterly Income from Non-Controlling Interests rose 2136.43% year-over-year to $315691.2 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $416834.7 (up 78.42% YoY) and the FY2023 annual result came in at $413160.9, up 84.07% from the prior year.
- Income from Non-Controlling Interests grew to $315691.2 in Q3 2023 per PRQR's latest filing, from $17422.8 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $315691.2 in Q3 2023 and troughed at -$98886.7 in Q1 2019.
- A 5-year average of $11938.2 and a median of -$9344.6 in 2020 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2019 and 2022: Income from Non-Controlling Interests slumped 238.78% in 2019, then soared 2846.79% in 2022.
- Over 5 years, Income from Non-Controlling Interests stood at -$49809.9 in 2019, then jumped by 73.67% to -$13115.2 in 2020, then sank by 65.73% to -$21735.4 in 2021, then soared by 85.92% to -$3060.7 in 2022, then soared by 10414.21% to $315691.2 in 2023.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $315691.2, $17422.8, and $83720.7 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | ProQR Therapeutics | 218.57 Mn | 82.18 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 315,691.24 |
| Jun 30, 2023 | 17,422.79 |
| Mar 31, 2023 | 83,720.66 |
| Dec 31, 2022 | -3,060.74 |
| Sep 30, 2022 | 14,115.84 |
| Jun 30, 2022 | 231,551.30 |
| Mar 31, 2022 | -8,978.70 |
| Dec 31, 2021 | -21,735.45 |
| Sep 30, 2021 | -25,944.32 |
| Jun 30, 2021 | -8,429.90 |
| Mar 31, 2021 | -13,268.60 |
| Dec 31, 2020 | -13,115.19 |
| Sep 30, 2020 | -9,344.62 |
| Jun 30, 2020 | -7,710.22 |
| Mar 31, 2020 | -25,390.60 |
| Dec 31, 2019 | -49,809.95 |
| Sep 30, 2019 | -57,861.96 |
| Jun 30, 2019 | -92,138.41 |
| Mar 31, 2019 | -98,886.71 |
| Dec 31, 2018 | -37,666.08 |